Suppr超能文献

免疫检查点抑制剂联合治疗合并下腔静脉癌栓的肾细胞癌。

Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi.

机构信息

Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan;

Department of Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan.

出版信息

In Vivo. 2022 Mar-Apr;36(2):1030-1034. doi: 10.21873/invivo.12798.

Abstract

BACKGROUND/AIM: The efficacy of immune checkpoint inhibitor (ICI) combinations in treating inferior vena cava (IVC) tumour thrombi has not yet been reported. We aimed to evaluate the clinical efficacy of ICIs for patients with renal cell carcinoma (RCC) and a concomitant IVC tumour thrombus.

PATIENTS AND METHODS

Three men and two women with RCC and an IVC tumour thrombus were administered ICIs in 2020-2021. Three and two patients received nivolumab plus ipilimumab and pembrolizumab plus axitinib therapy, respectively.

RESULTS

All ICI-treated patients showed tumour shrinkage. The IVC thrombus level was downstaged in two patients. The mean reduction in maximum primary tumour diameter and IVC thrombus height was 34 and 33 mm, respectively.

CONCLUSION

Presurgical ICI therapy in three patients who underwent radical nephrectomy with thrombectomy resulted in a modified surgical strategy and approach and reduced surgical risk. Thus, ICIs may treat select cases of RCC with an IVC tumour thrombus effectively.

摘要

背景/目的:免疫检查点抑制剂(ICI)联合治疗下腔静脉(IVC)肿瘤血栓的疗效尚未见报道。我们旨在评估ICI 治疗合并 IVC 肿瘤血栓的肾细胞癌(RCC)患者的临床疗效。

患者和方法

2020 年至 2021 年期间,3 名男性和 2 名女性 RCC 合并 IVC 肿瘤血栓患者接受了 ICI 治疗。其中 3 名和 2 名患者分别接受了纳武利尤单抗联合伊匹单抗和帕博利珠单抗联合阿昔替尼治疗。

结果

所有接受 ICI 治疗的患者均显示肿瘤缩小。2 名患者的 IVC 血栓分级下降。最大原发肿瘤直径和 IVC 血栓高度的平均缩小分别为 34mm 和 33mm。

结论

对 3 例接受根治性肾切除术加血栓切除术的患者进行术前 ICI 治疗,改变了手术策略和方法,降低了手术风险。因此,ICI 可能对选择的 IVC 肿瘤血栓 RCC 病例有效。

相似文献

5
Laparoscopic Radical Nephrectomy and Inferior Vena Cava Thrombectomy in the Treatment of Renal Cell Carcinoma.
Eur Urol. 2015 Jul;68(1):115-22. doi: 10.1016/j.eururo.2014.12.011. Epub 2014 Dec 19.
10
Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus.
Am J Surg. 2002 Mar;183(3):292-9. doi: 10.1016/s0002-9610(02)00782-1.

引用本文的文献

3
Impact of presurgical systemic therapy on perioperative outcomes of renal cell carcinoma with inferior vena cava tumor thrombus.
Int J Clin Oncol. 2025 Mar;30(3):532-538. doi: 10.1007/s10147-024-02680-3. Epub 2024 Dec 12.

本文引用的文献

3
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.
4
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
5
Surgical Resection of Malignancies Invading Inferior Level I and II. Issues Still Need to Be Discussed.
Anticancer Res. 2017 May;37(5):2523-2528. doi: 10.21873/anticanres.11594.
6
Limited benefit of targeted molecular therapy for inferior vena cava thrombus associated with renal cell carcinoma.
Int J Clin Oncol. 2017 Aug;22(4):767-773. doi: 10.1007/s10147-017-1119-9. Epub 2017 Apr 1.
8
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
World J Urol. 2014 Feb;32(1):109-14. doi: 10.1007/s00345-013-1088-1. Epub 2013 Apr 27.
10
Duplicated vena cava with tumor thrombus from renal cancer: use of venogram for safer operative planning.
Urology. 2012 Apr;79(4):e57-8. doi: 10.1016/j.urology.2011.06.044. Epub 2011 Aug 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验